In the SURMOUNT 1 trial, tirzepatide at doses of 5 mg, 10 mg and 15 mg were evaluated against placebo, with pooled tirzepatide groups resulting in significant decreases in total cholesterol, LDL-C, VLDL-C, FFA, and triglycerides and an increase in HDL-C at week 72 of follow-up [35]
20mg User Data (Anecdotal, n=thousands on r/Retatrutide, GLP1s): Risks (Elevated at 20mg) Bottom Line : High-risk, unproven
69 compared GSH blood concentrations in healthy young and healthy elderly subjects and found that the reference group of 20- to 39-year-old subjects (n = 40) had a GSH concentration 17% higher on average than the 60- to 79-year-old cohort of 60 subjects (mean SD, 547 53.5 g/10 10 vs
Further studies assessing the safety, effectiveness, and sustainability of these novel endoscopic techniques are warranted